The 505(b)(2) New Drug Application (NDA) provides a streamlined route for drug approval, making it a popular choice among many clients seeking FDA approval. Established by the Hatch-Waxman Amendments of 1984, this pathway refers to a specific section of the Federal Food, Drug, and Cosmetic Act.
Its inception aimed to eliminate the redundancy of conducting studies on drugs that have already received approval. In simpler terms, the 505(b)(2) provision allows the FDA to consider pre-existing data when reviewing an application, even if the applicant didn’t develop this data.
Under this application, full safety and effectiveness reports are mandatory. However, the 505(b)(2) provision permits the inclusion of data from external studies, specifically those about the safety and efficacy of the active ingredient. This exception accelerates the approval process and reduces associated costs when contrasted with the traditional 505(b)(1) pathway.
As a result, applicants can achieve FDA approval more efficiently and at a reduced cost while bringing innovative, high-value products to the market.
The FDA Group provides a versatile range of services designed to assist clients in crafting top-tier, compliant NDA submissions. We are equipped to accommodate diverse needs—from managing the complete NDA process to aiding in publishing and submission or reviewing specific documents.
Our team of consultants comprises former FDA reviewers and skilled professionals, including medical writers and project managers, all dedicated to supporting every aspect of your NDA preparation.
Reach out to us to explore how we can help you bring your product to market and keep it there.
The FDA recognizes three primary pathways for the approval of new drugs and abbreviated new drug applications (ANDA): the 505(b)(1) NDA , 505(j) ANDA , and 505(b)(2) NDA .
Each pathway serves a distinct purpose in the drug approval process.
The 505(b)(1) NDA is a comprehensive application that relies entirely on original data. Every study conducted under this pathway is specifically tailored for the drug by the sponsor and serves as the foundational data for FDA approval.
This pathway is the most resource-intensive and time-consuming of the three.
This pathway is designed for the approval of generic drugs. The 505(j) ANDA becomes relevant when a patented innovator drug is approaching its expiration.
The central criterion for approval through this pathway is demonstrating bioequivalence to the innovator product. For oral dosage forms, a food effect study is typically required to ensure similar efficacy and safety profiles.
A "hybrid application," the 505(b)(2) NDA, combines aspects of both the full NDA and ANDA. This pathway is ideal for modified or improved versions of existing innovator drugs, leading to the creation of a distinct drug product with its own exclusivity rights.
The process incorporates pre-existing data and new findings to facilitate a more efficient approval process. In Europe, a similar process is known as the Hybrid application, reflecting its combined nature.
In short , the 505(b)(2) pathway offers pharmaceutical companies a strategic advantage by reducing the time and financial investment typically required for the conventional full NDA. This approach bypasses the necessity for numerous nonclinical studies and extensive safety and efficacy tests.
The 505(b)(2) submission journey involves four crucial steps: candidate identification, candidate assessment, product planning, and the pre-IND meeting.
The first step involves selecting drug products compatible with the 505(b)(2) pathway, a crucial action that mitigates the risk of failure. It typically involves a few nonclinical studies.
This phase is critical for minimizing costly mistakes and validating the product concept’s value to investors.
At this stage, developers should strategically incorporate existing data to optimize their development plans.
Initiating the pre-IND meeting with the FDA is a pivotal step in the 505(b)(2) pathway, distinguished from the 505(b)(1) process in several ways, including the order of steps and the extent of required studies.
This meeting aims to secure FDA input and agreement on the planned studies and strategies, streamlining the approval process and enhancing investor attractiveness. Using public or previous FDA data can also reduce the need for additional studies, accelerating the timeline and reducing costs.
Let's dig into the details of the pre-IND meeting in a bit more clarifying detail:
The 505(b)(2) process begins with the pre-IND meeting, unlike the 505(b)(1), which starts with formulation development.
It then proceeds to formulation development and any necessary additional studies. The process concludes with the IND filing.
The 505(b)(2) process begins with the pre-IND meeting, unlike the 505(b)(1), which starts with formulation development.
It then proceeds to formulation development and any necessary additional studies. The process concludes with the IND filing.
Utilization of public data or previous FDA findings is a hallmark of the 505(b)(2) pathway. This allows for bridging studies, reducing the need for extensive clinical or nonclinical studies, a requirement in the 505(b)(1) pathway.
For Phase 1 studies, clinical trial materials should mirror the commercial manufacturing process, including packaging, in the 505(b)(2) pathway. Preparation of three stability batches for shelf-life determination is required early on, necessitating significant CMC work before study initiation. Contact us for specialized CMC or other consulting support.
The 505(b)(2) pathway’s reliance on existing data enables simultaneous initiation and parallel development of clinical studies. It’s possible to commence a Phase 3 study before completing all Phase 1 studies and without a Phase 2 study, leading to cost and time savings.
Again, the 505(b)(2) pathway allows applicants to leverage existing public literature or the FDA’s prior safety and effectiveness findings for an approved drug. It often applies to changes in already approved drugs or the introduction of a new chemical entity (NCE) without a right of reference to previous studies.
Key categories include:
Some examples of qualifications include:
Generally speaking, a product with such changes qualifies for the 505(b)(2) pathway if it establishes a scientific bridge to the approved “listed drug,” especially when the applicant lacks a right of reference to the original approval data.
Navigating the 505(b)(2) development pathway can be intricate, yet it unveils significant opportunities for sponsors aiming to expedite the drug approval process. The initial step involves meticulously comparing the new and innovator drugs, focusing intensely on their PK attributes.
To harness the full potential of the 505(b)(2) approach, a well-crafted "PK bridge" is instrumental.
Firms should seek a 505(b)(2) regulatory consultant when internal expertise, resources, or experience is limited.
As we've demonstrated time and again, consultants can be instrumental in complex developments, regulatory challenges, risk mitigation, strategic planning, FDA engagement, and post-approval support. Their role is pivotal in optimizing the submission process, reducing errors, and ensuring timely approval.
Below are a few key questions to consider that all speak to the need for a skilled regulatory consultant. Contact us to start the conversation.
The FDA Group offers exclusive access to a large staff of seasoned senior scientists and regulatory professionals proficient in both the strategic and operational facets of 505(b)(2) development programs. We are adept at combining regulatory insights with a broad spectrum of expertise in scientific, clinical, and nonclinical domains, ensuring a customized and effective pathway for each 505(b)(2) initiative.
Our track record includes active participation in numerous 505(b)(2) programs. We pride ourselves on offering comprehensive support, as exemplified in a case where we facilitated an end-to-end 505(b)(2) submission. Our role extended to managing FDA interactions and serving as the primary contact for regulatory affairs, ensuring seamless communication and coordination.
Reach out to us to explore how we can help you bring your product to market and keep it there.
FREE CASE STUDY
Learn how The FDA Group partnered with a healthcare product Company to support a series of international Quality Audits to assess both Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP) throughout the United States, Europe, Asia, and the Middle East.
